Development of agents for the treatment of systemic sclerosis

Bibliography

• MEDSGER TA, SILMAN AJ, STEEN VD et al.: A disease severity scale for systemic sclerosis: development and testing. Rheumatel (1999) 26:2159–2167.
   PubMed Web of Science ®Google Scholar
• DENTON CP, BLACK CM: Scleroderma and related disorders: therapeutic aspects. Best Piaci Res. Gun. Rheumatel(2000) 14:17–35.
   PubMed Web of Science ®Google Scholar
• •A comprehensive and up-to-date review of treatment of SSc.
   Google Scholar
• WHITE B, BAUER EA, GOLDSMITH LAet al: Guidelines for clinical trials in systemic sclerosis (scleroderma), I: disease-modifying interventions. Arthritis Rheum. (1995) 38:351–360.
   PubMed Web of Science ®Google Scholar
• HO M, VEALE D, EASTMOND C, NUKIG, BELCH J: Macrovascular disease and systemic sclerosis. Ann. Rheum. Dis. (2000) 59:39–43.
   PubMed Web of Science ®Google Scholar
• BRENNAN P, SILMAN A, BLACK C etal.,ON BEHALF OF THE UK SCLERODERMA STUDY GROUP: Reliability of skin involvement measures in scleroderma. Br. j Rheumatel (1992) 31:457–460.
   Google Scholar
• CLEMENTS P, LACHENBRUCH E SEIBOLD J et al.: Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. j Rheumatel (1995) 22:1281–1285.
   Google Scholar
• BLACK CM, SILMAN AJ, HERRICK ALet al.: Interferon-a does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo controlled trial. Arthritis Rheum. (1999) 42:299–305.
   Google Scholar
• •A controlled clinical trial in 35 patients with early diffuse disease.
   Google Scholar
• CLEMENTS PJ, FURST DE, WONG W- K et al.: High-dose versus low dose D-penicillamine in early diffuse systemic sclerosis. Arthritis Rheum. (1999) 42:1194–1203.
   Google Scholar
• •A controlled clinical trial in 134 patients with early diffuse SSc comparing D-penicillamine in high-dose (750–1000 mg daily) with low-dose (125 mg on alternate days).
   Google Scholar
• POPE J, BELLAMY N, SEIBOLD J et al: A randomized controlled trial of methotrexate versus placebo in early diffuse scleroderma - preliminary analysis. Arthritis Rheum. (1998) 41(Suppl.):8102.
   Google Scholar
• SEIBOLD JR, KORN JH, SIMMS R et al: Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann. Int. Med. (2000) 132:871–879.
   PubMed Web of Science ®Google Scholar
• •A controlled clinical trial in 68 patients with diffuse SSc of less than 5 years' duration, two different dose regimes of relaxin, given by continuous subcutaneous infusion, were compared with placebo.
   Google Scholar
• ENOMOTO DNH, MEKKES JR, BOSSUYT PMM et al.: Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photophoresis). j Am. Acad. DermatoL (1999) 41:915–922.
   PubMed Web of Science ®Google Scholar
• LE CH, MORALES A, TRENTHAM DE: Minocycline in early diffuse scleroderma. Lancet (1998) 352:1755–1756.
   PubMed Web of Science ®Google Scholar
• FILACI G, CUTOLO M, SCUDELETTI M et al.: Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. Rheumatology (1999) 38:992–996.
   PubMed Web of Science ®Google Scholar
• MORTON SJ, POWELL RJ: Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma. Rheumatology (2000) 39:865–869.
   PubMed Web of Science ®Google Scholar
• CLEMENTS PJ, LACHENBRUCH PA, STERZ M etal.: Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum. (1993) 36:75–83.
   Google Scholar
• POPE J, FENLON D, THOMPSON A et al.: Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis (Cochrane Review). In: The Cochrane Library Issue 4 (2000). Oxford: Update Software.
   Google Scholar
• AKESSON A: Cyclophosphamide therapyfor scleroderma. Curr. Opiri. RheumatoL (1998) 10:579–583.
   PubMedGoogle Scholar
• WHITE B, MOORE WC, WIGLEY FM, XIAO HQ, WISE RA: Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann. Int. Med. (2000) 132:947–954.
   PubMed Web of Science ®Google Scholar
• KLINGS ES, HILL NS, IEONG MH, SIMMS RW, KORN JH, FARBER HW: Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin). Arthritis Rheum. (1999) 42:2638–2645.
   PubMed Web of Science ®Google Scholar
• BADESCH DB, TAPSON VF, McGOON MD et al.: Continuous intravenous epoprostenol for pulmonary hypertension due to scleroderma spectrum of disease. A randomized, controlled trial. Ann. IrM Med. (2000) 132:425–434.
   PubMed Web of Science ®Google Scholar
• •A randomised open-label study of 111 patients with moderate-to-severe pulmonary hypertension, both exercise capacity and pulmonary haemodynamics improved after 12 weeks' prostacyclin (epoprostenol).
   Google Scholar
• MCLAUGHLIN VV, GENTHNER DE, PANELLA MM, RICH S: Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl. Med. (1998) 338:273–277.
   PubMed Web of Science ®Google Scholar
• QUERFELD C, ECKES B, HUERKAMP C, KREIG T, SOLIBERG S: Expression of TGF-I3 1, -132 and -133 in localized and systemic scleroderma. I DermatoL Sci. (1999) 21:13–22.
   PubMed Web of Science ®Google Scholar
• COTTON SA, HERRICK AL, JAYSONMIV, FREEMONT AJ: TGF-I3 - a role in systemic sclerosis. j PathoL (1998) 184:4–6.
   PubMedGoogle Scholar
• ABRAHAM DJ, SHIWEN X, BLACK CM, SA S, XU Y, LEASK A: Tumor necrosis factor a suppresses the induction of connective tissue growth factor by transforming growth factor-I3 in normal and scleroderma fibroblasts. j Biol. Chem. (2000) 275:15220–15225.
   PubMed Web of Science ®Google Scholar
• SHAH M, FOREMAN DM, FERGUSON MWJ: Control of scarring in adult wounds by neutralising antibody to transforming growth factor P. Lancet (1992) 339:213–214.
   PubMed Web of Science ®Google Scholar
• GRASSEGER A, SCHULER G, HESSENBERGER G et al.: Interferon-gamma in the treatment of systemic sclerosis: a randomised controlled multicentre trial. Br. j DermatoL (1998) 139:639–648.
   PubMed Web of Science ®Google Scholar
• HERRICK AL: Advances in treatment ofsystemic sclerosis. Lancet (1998) 352:1874–1875.
   PubMed Web of Science ®Google Scholar
• ANONYMOUS. Halofuginone hydrobromide. Drugs Fut. (2000) 25:635–636.
   Web of Science ®Google Scholar
• NAGLER A, PINES M: Topical treatmentof cutaneous graft versus host disease with halofuginine: a novel inhibitor of collagen Type I synthesis. Transplantation (1999) 68:1806–1809.
   PubMed Web of Science ®Google Scholar
• FISHMAN AP: Pulmonary hypertension -beyond vasodilator therapy. N Engl. I Med. (1998) 338:321–322.
   PubMed Web of Science ®Google Scholar
• KAHALEH MB, MATUCCI CERINIC M, FAN P-S: Modulation of endothelial gene expression by prostanoids in systemic sclerosis. Arthritis Rheum. (2000) 43(Abstract, Suppl.):5258.
   Google Scholar
• BLACK CM, HALKIER-SORENSEN L, BELCH JJF et al.: Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. Br RheumatoL (1998) 37:952–960.
   PubMedGoogle Scholar
• WIGLEY FM, KORN JH, CSUKA ME et al.: Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multi-center, placebo-controlled, double-blind study. Arthritis Rheum. (1998) 41:670–677.
   PubMed Web of Science ®Google Scholar
• •A large study of parallel group design, examining the effects of oral iloprost on digital vascular problems in SSc.
   Google Scholar
• JANSSEN MCH, WOLLERSHEIM H, KRAUS C, HILDEBRAND M, WATSON HR, THEIN T: Pharmacokinetics of oral iloprost in patients with Raynaud's phenomenon secondary to systemic sclerosis. Prostaglandins & other Lipid Mediators (2000) 60:153–160.
   PubMed Web of Science ®Google Scholar
• HOEPER MM, OLSCHEWSKI H, GHOFRANI HA et al.: A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. j Am. Coll. CardioL (2000) 35:176–182.
   PubMed Web of Science ®Google Scholar
• HOEPER MM, SCHWARZE M, EHLERDING S etal.: Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl. I Med. (2000) 342:1866–1870.
   Google Scholar
• McLAUGHLIN V, BARST R, RICH S et al.: Efficacy and safety of UT-15, a prostacyclin analogue, for primary pulmonary hypertension. Eur. Heart J. (1999) 20(Suppl):486.
   Google Scholar
• BARST RJ, SIMONNEAU G, RICH S, BLACKBURN SD, NAEIJE R, RUBIN LJ: Efficacy and safety of chronic subcutaneous infusion UT-15 in pulmonary arterial hypertension (PAH). Circulation (2000) 102 (Suppl. II):Abstract 477.
   Google Scholar
• MANCINI GB, HENRY GC, MACAYA C et al.: Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation (1996) 94:258–265.
   PubMed Web of Science ®Google Scholar
• BRILLA CG, FUNCK RC, RUPP H: Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation (2000) 102:1388–1393.
   PubMed Web of Science ®Google Scholar
• WEBER KT, BRILLA CG, JANICKI JS: Cardioreparation with lisinopril in the management of hypertension and heart failure. Cardiology(1991) 79\(Suppl. 1):6273.
   Google Scholar
• DZIADZIO M, DENTON CP, SMITH R et al.: Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum. (1999) 42:2646–2655.
   PubMed Web of Science ®Google Scholar
• NOBLE NA, BORDER WA: AngiotensinII in renal fibrosis: should TGF-I3 rather than blood pressure be the therapeutic target? Sem. Nephrol (1997) 17:455–466.
   Web of Science ®Google Scholar
• KIRCHENGAST M, MUNTER K: Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling. PSEBM (1999) 221:312–325.
   PubMed Web of Science ®Google Scholar
• HOCHER B, SCHWARZ A, FAGAN KA et al.: Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am. Resp. Cell Mal Biol. (2000) 23:7–10.
   PubMed Web of Science ®Google Scholar
• VANCHEESWARAN R, AZAM A, BLACK C, DASHWOOD MR: Localization of endothelin-1 and its binding sites in scleroderma skin. j Rheumatol (1994) 21:1268–1276.
   PubMed Web of Science ®Google Scholar
• ABRAHAM DJ, VANCHEESWARAN R, DASHWOOD MR: Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am. J. Pathol (1997) 151:831–841.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI H, NISHIMAKI T, KAISE S et al.: Immunological study of endothelin-1 and endothelin-A and B receptors in two patients with scleroderma renal crisis. Clin Rheumatol (1999) 18:425–427.
   PubMed Web of Science ®Google Scholar
• WILLIAMSON DJ, WALLMAN LL, JONES R et al.: Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation (2000) 102:411–418.
   PubMed Web of Science ®Google Scholar
• PRENDERGAST B, NEWBY DE, WILSON LE, WEBB DJ, MANKAD PS: Early therapeutic experience with the endothelin antagonist BQ-123 in pulmonary hypertension after congenital heart surgery. Heart (1999) 82:505–508.
   PubMed Web of Science ®Google Scholar
• BERGLER-KLEIN J, PACHER R, BERGER R, BOJIC A, STANEK B: Neurohumoral and hemodynamic effects of the selective endothelin antagonist LU 135252 in advanced heart failure. Circulation (2000) 102 (Suppl. II):2871 (Abstract).
   Google Scholar
• KENTSCH M, OTTER W: Novel neurohormonal modulators in cardiovascular disorders. The therapeutic potential of endopeptidase inhibitors. Drugs RD (1999) 1:331–338.
   Google Scholar
• YAMAMOTA T, KATAYAMA I, NICHIOKA K: Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis. Rheumatol (1998) 25:314–317.
   Web of Science ®Google Scholar
• COTTON SA, HERRICK AL, JAYS ON MIV, FREEMONT AJ: Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. Foam] (1999) 189:273–278.
   Google Scholar
• HAMPL V, HERGET J: Role of nitric oxide in the pathogenesis of chronic pulmonary hypertension. Physiol Rev (2000) 80:1337–1372.
   PubMed Web of Science ®Google Scholar
• •A very comprehensive review.
   Google Scholar
• KATAYAMA Y, HIGENBOTTAM T, CREMONA G et al.: Minimising the inhaled dose of NO with breath-to-breath delivery of spikes of concentrated gas. Circulation (1998) 98: 2429–2432.
   PubMed Web of Science ®Google Scholar
• WARREN JB, HIGENBOTTAM T: Caution with use of inhaled nitric oxide. Lancet (1996) 348: 629–630.
   PubMed Web of Science ®Google Scholar
• TEH LS, MANNING J, MOORE T, TULLY MP, O'REILLY D, JAYSON MIV: Sustained release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. Br. Rheumatol (1995) 34: 636–641.
   PubMedGoogle Scholar
• KHAN F, GREIG IR, NEWTON DJ, BUTLER AR, BELCH JJF: Skin blood flow after trandermal S-nitrosothio-acetylglucose. Lancet (1997) 350:410–411.
   PubMed Web of Science ®Google Scholar
• TUCKER AT, PEARSON RIVI, COOKE ED, BENJAMIN N: Effect of nitric-oxide-generating system on microcirculatory blood flow in skin in patients with severe Raynaud's syndrome: a randomised trial. Lancet (1999) 354:1670–1675.
   PubMed Web of Science ®Google Scholar
• KHAN E BELCH JJF: Skin blood flow in patients with systemic sclerosis and Raynaud's phenomenon: effects of oral L-arginine supplementation. j Rheumatol (1999) 26:2389–2394.
   PubMed Web of Science ®Google Scholar
• HERRICK AL, MATUCCI CERINIC M: The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin. Exp. Rheumatol (2001) 19:4–8.
   PubMed Web of Science ®Google Scholar
• DENTON CI BUNCE TD, DORADO MB et al: Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon. Rheumatology (1999) 38:309–315.
   PubMed Web of Science ®Google Scholar
• HERRICK AL, HOLLIS S, SCHOFIELD D et al.: A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. Clin Exp. Rheumatol (2000) 18:349–356.
   PubMed Web of Science ®Google Scholar
• DELANIAN S, BAILLET E HUART J, LEFAIX J-L, MAULARD C, HOUSSET M: Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase: clinical trial. Radiother. Oncol (1994) 32:12–20.
   PubMed Web of Science ®Google Scholar
• LEFAIX J-L, DELANIEN S, VOZENIN M-C, LEPLAT J-J, TRICAUD Y, MARTIN M: Striking regression of subcutaneous fibrosis induced by high doses of gamma rays using a combination of pentoxifylline and a-tocopherol: an experimental study. Int. j Rad. Oncol Biol. Phys. (1999) 43:839–847.
   PubMed Web of Science ®Google Scholar
• PAROLA M, MURACA R, DIANZANI I etal.: Vitamin E dietary supplementation inhibits transforming growth factor 131 gene expression in the rat liver. FEBS Lett. (1992) 308:267–270.
   Google Scholar
• THOMPSON WD, LI WW, MARAGOUDAKIS M: The clinical manipulation of angiogenesis: pathology, side effects, surprises, and opportunities with novel human therapies. j Pathol (2000) 190:330–337.
   PubMed Web of Science ®Google Scholar
• SIMONS M, BONOW BO, CHRONOS NA et al: Clinical trials in coronary angiogenesis: issues, problems, consensus: an expert panel summary. Circulation (2000) 102:e73–e86.
   PubMed Web of Science ®Google Scholar
• STRATTON RJ, WILSON H, BLACK CM: Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatol (2001) 40:84–88.
   PubMed Web of Science ®Google Scholar
• LIPSKY JJ: Mycophenolate mofetil. Lancet (1996) 348:1357–1359.
   PubMed Web of Science ®Google Scholar
• LORENZ H-M: Biological agents: a novel approach to the therapy of rheumatoid arthritis. Expert Opin. Investig. Drugs (2000) 9:1479–1490.
   PubMed Web of Science ®Google Scholar
• ELLMAN MH, MACDONALD PA, HAYES FA: Etanercept treatment for diffuse scleroderma: a pilot study. Arthritis Rheum. (2000) 43(Abstract, Suppl.):5392.
   Google Scholar
• SNOWDEN JA, BROOKS PM: Hematopoietic stem cell transplanation in rheumatic diseases. Cun: Opin. Rheumatol (1999) 11:167–172.
   PubMedGoogle Scholar
• CLEMENTS PJ, FURST DE: Choosing appropriate patients with systemic sclerosis for treatment by autologous stem cell transplantation. j. Rheumatal. (1997) 24 (Suppl. 48):85–88.
   Google Scholar
• BINKS M, PASSWEG JR, FURST D et al.:Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann. Rheum. Dis. (2001) 60:577–584.
   PubMed Web of Science ®Google Scholar
• McKOWN KM, CARBONE LD, BUSTILLO J, SEYER JM, KANG AH, POSTLETHWAITE AE: Induction of immune tolerance to human Type I collagen in patients with systemic sclerosis by oral administration of bovine Type I collagen. Arthritis Rheum. (2000) 43:1054–1061.
   PubMed Web of Science ®Google Scholar
• •An interesting new approach to treatment.
   Google Scholar
• UK SCLERODERMA STUDY GROUP: How can treatment of systemic sclerosis be improved? BMJ(1998) 317:294–295.
   Google Scholar